Trial Profile
Phase III comparative study of KRP-108 -Open-label, active-controlled, crossover comparative study of KRP-108 in pediatric bronchial asthma-
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Formoterol/fluticasone propionate (Primary) ; Fluticasone propionate; Salmeterol
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Kyorin Pharmaceutical
- 29 Jun 2020 According to a Kyorin Pharmaceutical media release, the company has received approval form the Ministry of Health, Labour and Welfare for a partial change in dosage and administration to add an indication for the pediatric use of Flutiform 50 Aerosol - 56 inhalations and Flutiform 50 Aerosol - 120 inhalations, a combination drug for asthma treatment.
- 03 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 01 Aug 2017 Status changed from not yet recruiting to recruiting.